

# 2016 BIOTECH OUTLOOK

Luncheon/Webcast • April 7, 2016 • Penn Club

Free Webcast for ACS National Members – Register at [www.cmeacs.org](http://www.cmeacs.org)

## Abstract

It has been a wild ride. After years of outperforming the S&P 500, the biotech sector found itself seriously affected in the recent market correction.

Substantial investments made during the last few years resulted in a vibrant biotech community with a healthy flow of safe and effective new drugs.

Much remains to be accomplished in the translation of promising candidates into approved products and its impact on the city of New York—which has been offering generous benefits for technology entrepreneurs—as it reaffirms its intent to become a world center for biotech innovation. April 7 is your opportunity to hear the insights of biotech experts about the challenges and opportunities in this exciting field.



**JMP**

**Speaker: Michael King, PhD**, is Michael King Jr is a Managing Director and senior research analyst covering the biotechnology industry. Prior to joining JMP, Mr King Jr was a Managing Director at Dawson James Securities, where he served as Director of Research and as a senior biotechnology analyst. He was previously a Managing Director and senior research analyst at Rodman & Renshaw, a Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology, and a Managing Director and senior equity analyst at Wedbush Securities. Beforehand, Mr King Jr served as a Managing Director and senior biotechnology analyst both at Merriman Curhan Ford and at Rodman & Renshaw, where, in his initial tenure with the company, he was also the Director of Research. Additionally, Mr King Jr has held senior equity research positions at Banc of America Securities, Robertson Stephens, Vector Securities and Dillon Read & Co, covering a wide range of market capitalizations and therapeutic categories. He began his career as a biotechnology specialist in the private client sales divisions of Alex Brown & Co, Hambrecht & Quist and Kidder, Peabody & Co. In 2013, Mr King Jr ranked first among all stock pickers in the Pharmaceuticals category in the annual “Best on the Street” analyst survey conducted by The Wall Street Journal. Mr King Jr holds a BA in finance from The Bernard M Baruch College of the City University of New York.

## Event Schedule

### Location:

Penn Club  
30 W 44th Street, NYC

### Event Times: (ET)

11:15 am - 12:00 noon  
Registration and  
Networking  
12 noon - 1 pm Luncheon  
1 pm - 2 pm Talk - Webcast

### Luncheon Fees

\$120 for non-members

\$90 for members

Check for Early-bird savings

**Webcast** : \$30. Free webcast recording for ACS members

### Event Host

Paul Pospisil

### CME Board

#### Chair

Charles Brumlik

#### Vice Chair

Guy Penard

#### Program Chair

James Weatherall

#### Secretary

Adam Closson

#### Treasurer

Karin Bartels

#### Directors

Neil Burns

Chris Cerimele

David J. Deutsch

Brian Orkin

Paul Pospisil

### Student Volunteers

Paloma Beraldo

Anne Powers

Anahit Stepanyan

Debra Rooker

Xiao Zhong

**LEADERSHIP  
Awards™**  
December 6, 2016

[www.cmeacs.org](http://www.cmeacs.org)

Luncheon/Webcast • April 7, 2016 • Penn Club (continued)



**NEW YORK  
BIO**

**Nathan Tinker** Nathan Tinker has been Executive Director of New York BIO since 2007. He has more than 20 years of experience in working with both global and emerging technology companies. Prior to joining NYBIO, he served as Executive Director of the Sabin Vaccine Institute Cancer Vaccine Consortium and as the Director of the Nanotechnology and Biotechnology Practice at Antenna Group. Dr. Tinker was Co-Founder and Executive Vice President of the NanoBusiness Alliance. He began his career in market research serving such clients as Apple, Sprint, Cantor Fitzgerald, DaimlerChrysler, Yahoo! and CSX. Dr. Tinker is in the advisory boards of Physicians Interactive Holdings, Viral Genetics, Versilant Technologies and the Nanotechnology Commercialization Association.



 **KORN FERRY**

**Paul Pospisil** is a Senior Client Partner, Global Life Sciences at KornFerry. His primary focus is to assist biotechnology and biopharmaceutical companies in recruiting for positions such as chief executive officer, chief business officer, head of research and development and other key executives. With over fifteen years in the industry as a successful executive and investor, Dr. Pospisil brings a thoughtful perspective to executive search, shaped by a breadth of experiences in company building, operational leadership and board functions from start-up, growth to mature companies. Prior to joining Korn Ferry, Dr. Pospisil was a co-founder and managing partner of both Aduro Capital LLC, and Aduro Partners LLC. He has worked at Atlas Venture, Millennium Pharmaceuticals and Altus Biologics. Dr. Pospisil holds a PhD in organic chemistry from Harvard University and a bachelor's degree in biochemistry from NYU. He attended Harvard Business School's Program for Management Development (PMD).

## Event Schedule

### Location:

Penn Club  
30 W 44th Street, NYC

### Event Times: (ET)

11:15 am - 12:00 noon  
Registration and  
Networking  
12 noon - 1 pm Luncheon  
1 pm - 2 pm Talk - Webcast

### Luncheon Fees

\$120 for non-members  
\$90 for members  
Check for Early-bird savings  
**Webcast** : \$30. Free webcast  
recording for ACS members

### Event Host

Adam Closson

## CME Board

### Chair

Charles Brumlik

### Program Chair

James Weatherall

### Secretary

Adam Closson

### Treasurer

Karin Bartels

### Directors

Neil Burns  
Chris Cerimele  
David J. Deutsch  
Rhoda Kriesel  
Brian Orkin  
Guy Penard  
Paul Pospisil

### Student Volunteers

Karin Gomez  
Paloma Beraldo  
Anne Powers  
Anahit Stepanyan  
Debra Rooker  
Xiao Zhong

**LEADERSHIP  
Awards™**  
December 8, 2015

[www.cmeacs.org](http://www.cmeacs.org)